VC
SNDX icon

Vivo Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Vivo Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-320,000
Closed -$6.12M – 62
2021
Q3 		$6.12M Hold
320,000
– – 0.27% 48
2021
Q2 		$5.49M Hold
320,000
– – 0.24% 53
2021
Q1 		$7.16M Buy
+320,000
New +$7.23M 0.25% 51

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vivo Capital's SNDX Position: Q4 2021 in Review

Vivo Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 320,000 shares — an estimated $6.12M sold.

Vivo Capital first reported a position in SNDX in Q1 2021 and held it in 3 quarters. The position peaked at $7.16M in Q1 2021. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Vivo Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Vivo Capital sold 320,000 Syndax Pharmaceuticals shares in Q4 2021, an estimated $6.12M.
  • Vivo Capital first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Vivo Capital's Syndax Pharmaceuticals position peaked at $7.16M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Vivo Capital's 13F filing for Q4 2021, filed 11 Feb 2022.